Committee for Advanced Therapies (CAT)
Minutes of the meeting on 04-06 October 2023

Chair: Ilona Reischl; Vice-Chair: Kieran Breen

Disclaimers

Some of the information contained in these minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CAT meeting reports once the procedures are finalised.

Of note, these minutes are a working document primarily designed for CAT members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to ongoing procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).
Table of contents

1. **Introduction** 6

1.1. Welcome and declarations of interest of members, alternates and experts 6

1.2. Adoption of agenda 6

1.3. Adoption of the minutes 6

2. **Evaluation of ATMPs** 6

2.1. Opinions 6

2.2. Oral explanations 6

2.3. Day 180 list of outstanding issues 7

2.4. Day 120 list of questions 7

2.5. Day 80 assessment reports 7

2.6. Update on ongoing initial applications 7

2.7. New applications 7

2.8. Withdrawal of initial marketing authorisation application 7

2.9. Re-examination of initial application procedures under Article 9(2) of Regulation No. 726/2004 7

2.10. Companion diagnostics 7

2.10.1. Initial consultation 7

2.10.2. Follow-up consultation 7

2.11. Type II variations and variations of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008 7

2.11.1. Breyanzi - lisocabtagene maraleucel / lisocabtagene maraleucel - EMEA/H/C/004731/II/0019 7

2.11.2. Breyanzi - lisocabtagene maraleucel / lisocabtagene maraleucel - EMEA/H/C/004731/II/0028/G 8

2.11.3. CARVYKTI - ciltacabtagene autoleucel - Orphan - EMEA/H/C/005095/II/0023 8

2.11.4. Upstaza - eladocagene exuparvovec - Orphan - EMEA/H/C/005352/II/0014/G 8

2.11.5. Yescarta - axicabtagene ciloleucel - Orphan - EMEA/H/C/004480/II/0063 9

2.12. Extension applications 9


2.12.2. Holoclar - ex vivo expanded autologous human corneal epithelial cells containing stem cells - Orphan - EMEA/H/C/002450/R/0058 9

2.12.3. Kymriah - tisagenlecleucel - Orphan - EMEA/H/C/004090/ANX/009.6 10

2.12.4. Libmeldy - atidarsagene autotemcel - Orphan - EMEA/H/C/005321/REC/009 10

2.12.5. Tecartus - brexucabtagene autoleucel - EMEA/H/C/005102/R/0034 10

2.12.6. Hemgenix - etranacogene dezaparvovec - EMEA/H/C/4827/R/0007 10

2.14. GMP and GCP inspections requests 11
3. Certification of ATMPs

3.1. Opinion

3.2. Day 60 Evaluation Reports

3.3. New Applications

4. Scientific Recommendation on Classification of ATMPs

4.1. New requests – Appointment of CAT Coordinator

4.1.1. Allogeneic peripheral blood-derived HSPC, Treg cells and Tcon cells

4.1.2. Spermatogonial stem cells, propagated in vitro

4.1.3. Live, freeze-dried, genetically modified Lactococcus lactis strain, engineered to secrete human interleukin-10 (hIL-10) and a deamidated, human leukocyte antigen (HLA)-DQ2 restricted, 33-mer alpha-gliadin peptide (dDQ2)

4.1.4. Autologous lymphocytes enriched in activated natural killer cells

4.1.5. Umbilical cord blood leukocyte concentrate containing cord blood stem cells

4.1.6. Umbilical cord blood leukocyte concentrate containing cord blood stem cells

4.1.7. DNA plasmid expressing short hairpin RNA (shRNA) against lytic origin of DNA replication of Epstein Barr Virus (EBV) messenger RNA (mRNA)

4.1.8. DNA plasmid expressing short hairpin RNA (shRNA) against BCL2 anti-apoptotic messenger RNA (mRNA)

4.2. Day 30 ATMP scientific recommendation

4.2.1. Devitalised cell-derived cartilaginous tissue

4.3. Day 60 revised scientific recommendation (following list of questions)

4.4. Finalisation of procedure

4.4.1. Allogeneic ex-vivo expanded pluripotent stem cell-derived cardiac ventricular progenitor cells

4.4.2. Allogeneic ex-vivo expanded pluripotent stem cell-derived photoreceptor progenitor cells

4.4.3. Allogeneic genetically modified human induced pluripotent stem cell-derived retinal pigment epithelial cells

4.4.4. Autologous cultured fibroblasts

4.4.5. Secretome (conditioned medium) from donor bone marrow mesenchymal stem cells (MSCs) containing cytokines, growth factors, proteins and extracellular vesicles

4.5. Follow-up and guidance

5. Scientific Advice

5.1. New requests - appointment of CAT Rapporteurs

5.1.1. Ongoing scientific advice procedures - Appointment of CAT Peer Reviewers

5.1.2. Scientific advice procedures starting at the next SAWP meeting

5.2. Procedures discussed at SAWP – 1st reports, D40 JRs, LoIs

5.3. Finalisation of D70 procedures – feedback from the discussion meeting

5.4. Final Advice Letters for procedures finalised the previous month
### 6. Pre-Authorisation Activities

#### 6.1. Paediatric investigation plans

#### 6.2. ITF briefing meetings in the field of ATMPs

#### 6.3. Priority Medicines (PRIME) – Eligibility requests

#### 6.3.1. Month 0 - Start of the procedure

#### 6.3.2. Month 1 – Discussion of eligibility

#### 6.3.3. Month 2 – Recommendation of eligibility

#### 6.3.4. Ongoing support

### 7. Organisational, regulatory and methodological matters

#### 7.1. Mandate and organisation of the CAT

#### 7.1.1. CAT membership

#### 7.1.2. Vote by proxy

#### 7.1.3. CAT Strategic Review & Learning meeting (SRLM) under the Spanish presidency, 25-27 October 2023 Madrid (Spain)

#### 7.1.4. Onboarding Program for CAT members and alternates

#### 7.1.5. Training on IRIS for the use of CAT members

#### 7.1.6. Refresher on CAT SAWP interactions

#### 7.2. Coordination with EMA Scientific Committees

#### 7.2.1. Frequently asked questions on medicinal products development and assessment involving companion diagnostic (CDx)

#### 7.2.2. Update on the interphase with the Medical Device Regulation (MDR)

#### 7.2.3. EPAR development

#### 7.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

#### 7.4. Cooperation with the EU regulatory network

#### 7.4.1. Support to member states for the assessment of ATMP Marketing Authorisation Applications

#### 7.5. Cooperation with international regulators

#### 7.5.1. ATMP cluster teleconference with US-FDA, Health Canada and PMDA (Japan)

#### 7.5.2. International Pharmaceutical Regulatory Programme (IPRP) Gene and Cell therapy working group

#### 7.6. CAT work plan

#### 7.6.1. CAT work plan for 2024

#### 7.6.2. Guideline on quality, non-clinical and clinical requirement for investigational ATMPs in clinical trials

#### 7.7. Planning and reporting

#### 7.8. Others

#### 7.8.1. Training of CAT members and assessors

#### 7.8.2. FDA Draft Guidance on Manufacturing Changes and Comparability for Human Cellular and Gene Therapy Products
<table>
<thead>
<tr>
<th></th>
<th>Any other business</th>
<th>20</th>
</tr>
</thead>
<tbody>
<tr>
<td>9</td>
<td>List of participants</td>
<td>20</td>
</tr>
<tr>
<td>10</td>
<td>Explanatory notes</td>
<td>24</td>
</tr>
</tbody>
</table>
1. **Introduction**

1.1. **Welcome and declarations of interest of members, alternates and experts**

The Chairperson opened the meeting by welcoming all participants. The meeting was held in-person with some members connected remotely.

In accordance with the Agency’s policy on handling of declarations of interests of scientific committees’ members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and on the topics in the agenda of the current meeting, the Committee Secretariat announced the restricted involvement of some Committee members, alternates and experts for concerned agenda topics.

Participants were asked to declare any changes, omissions or errors to their declared interests and/or additional restrictions concerning the matters for discussion. No new or additional interests or restrictions were declared. Restrictions applicable to this meeting are captured in the List of participants included in the minutes.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure. All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.

1.2. **Adoption of agenda**

The CAT agenda for 04-06 October 2023 meeting was adopted.

1.3. **Adoption of the minutes**

The CAT minutes for 06-09 September 2023 meeting were adopted. Feedback was provided on Upstaza II/13 (see point 2.11.11 in the September CAT minutes). The next discussion on this variation is expected to take place in the January 2024 CAT meeting.

2. **Evaluation of ATMPs**

2.1. **Opinions**

No items

2.2. **Oral explanations**

No items
2.3. **Day 180 list of outstanding issues**
No items

2.4. **Day 120 list of questions**
No items

2.5. **Day 80 assessment reports**
No items

2.6. **Update on ongoing initial applications**
No items

2.7. **New applications**
No items

2.8. **Withdrawal of initial marketing authorisation application**
No items

2.9. **Re-examination of initial application procedures under Article 9(2) of Regulation No. 726/2004**
No items

2.10. **Companion diagnostics**

2.10.1. **Initial consultation**
No items

2.10.2. **Follow-up consultation**
No items

2.11. **Type II variations and variations of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008**

2.11.1. **Breyanzi - lisocabtagene maraleucel / lisocabtagene maraleucel - EMEA/H/C/004731/II/0019**
Bristol-Myers Squibb Pharma EEIG
Rapporteur: Concetta Quintarelli
Scope: Quality, opinion
**Action:** for adoption
Request for supplementary information adopted on 16.06.2023.
The opinion was adopted.

2.11.2. **Breyanzi - lisocabtagene maraleucel / lisocabtagene maraleucel - EMEA/H/C/004731/II/0028/G**

Bristol-Myers Squibb Pharma EEIG
Rapporteur: Concetta Quintarelli
Scope: Quality, opinion
**Action:** for adoption
The opinion was adopted.

2.11.3. **CARVYKTI - ciltacabtagene autoleucel - Orphan - EMEA/H/C/005095/II/0023**

Janssen-Cilag International NV
Rapporteur: Jan Mueller-Berghaus
Scope: Quality, request for supplementary information
**Action:** for adoption
The request for supplementary information was adopted.

2.11.4. **Upstaza - eladocagene exuparvovec - Orphan - EMEA/H/C/005352/II/0014/G**

PTC Therapeutics International Limited
Rapporteur: Maura O'Donovan
Scope: Clinical, request for supplementary information
Update of sections 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC in order to update information on safety and efficacy, based on final results from studies NTUH-AADC-010 and NTUH-AADC-011. NTUH-AADC-010 is an open-label, single arm, externally controlled trial to evaluate safety, efficacy, pharmacodynamics and immunogenicity of AGIL-AADC in children from 18 months to less than 18 years of age with severe aromatic L-amino acid decarboxylase (AADC) deficiency, while NTUH-AADC-011 is an open-label, single arm, externally controlled trial to evaluate efficacy and safety of AGIL-AADC in children from 18 months to less than 6 years of age with severe AADC deficiency. In addition, sections 4.5, 4.9 and 6.6 of the SmPC are updated in order to provide better clarification and guidance for the medical practice. The Package Leaflet is updated accordingly. The MAH also took the opportunity to update the due date of the final report of study AADC-1602 in the Annex II, considering the 10-year follow up of the last patient in study AADC-011, and to introduce minor editorial changes to the product information (PI).
**Action:** for adoption
The Rapporteur presented the assessment of this type II variation. The request for supplementary information was adopted.

2.11.5. **Yescarta - axicabtagene ciloleucel - Orphan - EMEA/H/C/004480/II/0063**

Kite Pharma EU B.V.

Rapporteur: Jan Mueller-Berghaus

Scope: Clinical, request for supplementary information

Update of section 5.1 of the SmPC in order to include new clinical data based on Overall Survival (OS) Primary Analysis from study KTE-C19-107 (ZUMA-7); this is a phase 3, randomised, open-label study evaluating the efficacy of axicabtagene ciloleucel versus standard of care therapy in subjects with relapsed/refractory diffuse large B cell lymphoma (DLBCL) in the 2nd line setting. In addition, the MAH took the opportunity to submit a consolidated Environmental Risk Assessment (ERA) document.

**Action:** for adoption

The request for supplementary information was adopted.

2.12. **Extension applications**

No items

2.13. **Other Post-Authorisation Activities**

2.13.1. **Breyanzi - lisocabtagene maraleucel / lisocabtagene maraleucel - EMEA/H/C/004731/REC/015**

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Concetta Quintarelli

Scope: Quality, request for supplementary information

**Action:** for adoption

The request for supplementary information was adopted.

2.13.2. **Holoclar - ex vivo expanded autologous human corneal epithelial cells containing stem cells - Orphan - EMEA/H/C/002450/R/0058**

Holostem Terapie Avanzate s.r.l.

Rapporteur: Egbert Flory, Co-Rapporteur: Concetta Quintarelli, PRAC Rapporteur: Rhea Fitzgerald

Scope: 1 year renewal of marketing authorisation, request for supplementary information

**Action:** for adoption

The Rapporteur presented the assessment of the renewal application for Holoclar. The
request for supplementary information was adopted.

### 2.13.3. Kymriah - tisagenlecleucel - Orphan - EMEA/H/C/004090/ANX/009.6

**Novartis Europharm Limited**

**Rapporteur:** Rune Kjeken

**Scope:** Pharmacovigilance, request for supplementary information

**From Initial MAA:**

**Study CCTL019H2301:**

**Post-authorisation efficacy study (PAES):**

In order to further characterise the long-term efficacy and safety of Kymriah in relapsed/refractory Diffuse large B cell lymphoma (DLBCL), the applicant should submit the final overall survival results of study CCTL019H2301 – open-label, Phase III study of Kymriah versus standard of care in adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.

**Action:** for adoption

The Rapporteur presented the assessment of this post-authorisation measure. The request for supplementary information was adopted.

### 2.13.4. Libmeldy - atidarsagene autotemcel - Orphan - EMEA/H/C/005321/REC/009

**Orchard Therapeutics (Netherlands) B.V.**

**Rapporteur:** Johannes Hendrikus Ovelgonne

**Scope:** Quality, opinion

**Action:** for adoption

The opinion was adopted.

### 2.13.5. Tecartus - brexucabtagene autoleucel - EMEA/H/C/005102/R/0034

**Kite Pharma EU B.V.**

**Rapporteur:** Jan Mueller-Berghaus, Co-rapporteur: Rune Kjeken, PRAC Rapporteur: Menno van der Elst

**Scope:** Annual renewal (with RMP)

**Action:** for adoption

The Rapporteur presented the assessment of this renewal application. The annual renewal was adopted.

### 2.13.6. Hemgenix - etranacogene dezaparvovec - EMEA/H/C/4827/R/0007

**CSL Behring GmbH**
Rapporteur: Silke Dorner, PRAC Rapporteur: Menno van der Elst

Scope: Annual renewal

**Action:** for adoption

The annual renewal was adopted.

### 2.14. GMP and GCP inspections requests

No items

### 3. Certification of ATMPs

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

#### 3.1. Opinion

No items

#### 3.2. Day 60 Evaluation Reports

No items

#### 3.3. New Applications

No items

### 4. Scientific Recommendation on Classification of ATMPs

**Timetable:**
- Start of the procedure: 10.10.2023
- EMA Coordinator’s draft report: 20.10.2023
- CAT Coordinator’s comments: 24.10.2023
- Revised scientific recommendation: 25.10.2023
- CAT’s discussion of scientific recommendation: 31.10.2023

#### 4.1. New requests – Appointment of CAT Coordinator

#### 4.1.1. Allogeneic peripheral blood-derived HSPC, Treg cells and Tcon cells

Prevention of moderate to severe chronic graft-vs.-host disease and/or death in patients with acute leukaemias and in patients with myelodysplastic syndrome (MDS) undergoing human leukocyte antigen (HLA)-matched allogeneic hematopoietic stem cell transplant (alloHCT)

Scope: Appointment of CAT Coordinator and adoption of timetable
**Action:** for adoption

The CAT Coordinator was appointed.

---

### 4.1.2. Spermatogonial stem cells, propagated in vitro

Male infertility due to gonadotoxic treatment

**Scope:** Appointment of CAT Coordinator and adoption of timetable

**Action:** for adoption

The CAT Coordinator was appointed.

---

### 4.1.3. Live, freeze-dried, genetically modified Lactococcus lactis strain, engineered to secrete human interleukin-10 (hIL-10) and a deamidated, human leukocyte antigen (HLA)-DQ2 restricted, 33-mer alpha-gliadin peptide (dDQ2)

Treatment of celiac disease

**Scope:** Appointment of CAT Coordinator and adoption of timetable

**Action:** for adoption

The CAT Coordinator was appointed.

---

### 4.1.4. Autologous lymphocytes enriched in activated natural killer cells

Cancer

**Scope:** Appointment of CAT Coordinator and adoption of timetable

**Action:** for adoption

The CAT Coordinator was appointed.

---

### 4.1.5. Umbilical cord blood leukocyte concentrate containing cord blood stem cells

Hypoxic-ischaemic encephalopathy

**Scope:** Appointment of CAT Coordinator and adoption of timetable

**Action:** for adoption

The CAT Coordinator was appointed.

---

### 4.1.6. Umbilical cord blood leukocyte concentrate containing cord blood stem cells

Cerebral palsy

**Scope:** Appointment of CAT Coordinator and adoption of timetable

**Action:** for adoption

The CAT Coordinator was appointed.
4.1.7. DNA plasmid expressing short hairpin RNA (shRNA) against lytic origin of DNA replication of Epstein Barr Virus (EBV) messenger RNA (mRNA)

Treatment of EBV infected patients
Scope: Appointment of CAT Coordinator and adoption of timetable

Action: for adoption

The CAT Coordinator was appointed.

4.1.8. DNA plasmid expressing short hairpin RNA (shRNA) against BCL2 anti-apoptotic messenger RNA (mRNA)

Treatment of cancer patients
Scope: Appointment of CAT Coordinator and adoption of timetable

Action: for adoption

The CAT Coordinator was appointed.

4.2. Day 30 ATMP scientific recommendation

4.2.1. Devitalised cell-derived cartilaginous tissue

Bone substitute for maxillofacial and/or orthopaedic bone defects
Scope: ATMP scientific recommendation

Action: for adoption

CAT discussed the classification report. CAT Secretariat to send the draft scientific recommendation to the European Commission for comments by 20.10.2023.

4.3. Day 60 revised scientific recommendation (following list of questions)

No items

4.4. Finalisation of procedure

4.4.1. Allogeneic ex-vivo expanded pluripotent stem cell-derived cardiac ventricular progenitor cells

Intended for the treatment of chronic and acute heart disease
Scope: European Commission raised no comments. ATMP scientific recommendation

Action: for adoption

The classification report was adopted. The product does fulfil the definition of a tissue engineered product as provided in Article 2(1) of Regulation (EC) No 1394/2007.
4.4.2. **Allogeneic ex-vivo expanded pluripotent stem cell-derived photoreceptor progenitor cells**

Intended for the treatment of retinitis pigmentosa

Scope: European Commission raised no comments. ATMP scientific recommendation

**Action:** for adoption

The classification report was adopted. The product does fulfil the definition of a tissue engineered product as provided in Article 2(1) of Regulation (EC) No 1394/2007.

4.4.3. **Allogeneic genetically modified human induced pluripotent stem cell-derived retinal pigment epithelial cells**

Intended for the treatment of Stargardt indication

Scope: European Commission raised no comments. ATMP scientific recommendation

**Action:** for adoption

The classification report was adopted. The product does fulfil the definition of a tissue engineered product as provided in Article 2(1) of Regulation (EC) No 1394/2007.

4.4.4. **Autologous cultured fibroblasts**

Intended for the treatment of scars and wounds

Scope: European Commission raised no comments. ATMP scientific recommendation

**Action:** for adoption

The classification report was adopted. The product does fulfil the definitions of a somatic cell therapy medicinal product and a tissue engineered product, and is therefore classified as a tissue engineered product as provided in Article 2(4) of Regulation (EC) No 1394/2007.

4.4.5. **Secretome (conditioned medium) from donor bone marrow mesenchymal stem cells (MSCs) containing cytokines, growth factors, proteins and extracellular vesicles**

Intended for the treatment of paediatric respiratory diseases called childhood interstitial lung disease (ChILD)

Scope: European Commission raised no comments. ATMP scientific recommendation

**Action:** for adoption

The classification report was adopted. The product does not fulfil the definition of an advanced therapy medicinal product as provided in Article 2(1) of Regulation (EC) No 1394/2007.

4.5. **Follow-up and guidance**

No items
5. **Scientific Advice**

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

5.1. **New requests - appointment of CAT Rapporteurs**

5.1.1. **Ongoing scientific advice procedures - Appointment of CAT Peer Reviewers**

Timetable:
- Start of procedure at SAWP: 25-28.09.2023
- Appointment of CAT Peer Reviewers: 04-06.10.2023
- SAWP first reports: 16.10.2023
- CAT Peer Reviewer comments (NC/C): 20.10.2023
- CAT Peer Reviewer comments (Q): 25.10.2023
- Discussion at SAWP: 23-26.10.2023
- Discussion at CAT and feedback to SAWP: 30-31.10.2023

5.1.2. **Scientific advice procedures starting at the next SAWP meeting**

Timetable:
- Start of procedure at SAWP: 23-26.10.2023
- Appointment of CAT Peer Reviewers: 30-31.10.2023
- SAWP first reports: 20.10.2023
- CAT Peer Reviewer comments (NC/C): 24.11.2023
- CAT Peer Reviewer comments (Q): 29.11.2023
- Discussion at SAWP: 27-30.11.2023
- Discussion at CAT and feedback to SAWP: 06-08.12.2023

5.2. **Procedures discussed at SAWP – 1st reports, D40 JR, LoIs**

5.3. **Finalisation of D70 procedures – feedback from the discussion meeting**

No items

5.4. **Final Advice Letters for procedures finalised the previous month**

6. **Pre-Authorisation Activities**

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

6.1. **Paediatric investigation plans**

No items
6.2. ITF briefing meetings in the field of ATMPs

No items

6.3. Priority Medicines (PRIME) – Eligibility requests

6.3.1. Month 0 - Start of the procedure

<table>
<thead>
<tr>
<th>Timetable for assessment:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Procedure start:</td>
</tr>
<tr>
<td>SAWP recommendation:</td>
</tr>
<tr>
<td>CAT recommendation:</td>
</tr>
<tr>
<td>CHMP adoption of report and final recommendation:</td>
</tr>
</tbody>
</table>

No items

6.3.2. Month 1 – Discussion of eligibility

6.3.3. Month 2 – Recommendation of eligibility

6.3.4. Ongoing support

No items

7. Organisational, regulatory and methodological matters

7.1. Mandate and organisation of the CAT

7.1.1. CAT membership

No items

7.1.2. Vote by proxy

No items

7.1.3. CAT Strategic Review & Learning meeting (SRLM) under the Spanish presidency, 25-27 October 2023 Madrid (Spain)

CAT: Sol Ruiz, Marcos Timon
Scope: Agenda of the upcoming SRLM
**Action**: for discussion
The latest agenda of the SRLM was presented.

### 7.1.4. Onboarding Program for CAT members and alternates

**CAT**: Ilona Reischl
**Scope**: Presentation of document and buddy system for new CAT members and alternates

**Action**: for discussion

The content of the onboarding programme document was presented: CAT members were asked to review it and identify if additional topics relevant for new CAT members need to be added. Comments are awaited by 16 October 2023.

The introduction of a buddy system for new members and alternates was agreed. This will be an optional system, on request of the new member.

### 7.1.5. Training on IRIS for the use of CAT members

**Scope**: Training on how CAT members can use IRIS for scientific advice (SA) and PRIME reports

**Action**: for information

The use of IRIS for retrieving SA and PRIME reports and for saving presentations, reports and SA peer review documents was explained.

### 7.1.6. Refresher on CAT SAWP interactions

**Scope**: Refreshing training on roles of CAT Peer Reviewers for SA

**Action**: for information

A short refresher training was provided on the role of the SA Peer Reviewer: the procedure has been updated on how to use IRIS to save peer reviews and presentations.

### 7.2. Coordination with EMA Scientific Committees

#### 7.2.1. Frequently asked questions on medicinal products development and assessment involving companion diagnostic (CDx)

**CAT**: Ilona Reischl
**Experts**: Joerg Engelbergs, Olga Kholmanskikh
**Scope**: Update from the Companion Diagnostics Expert Group

**Action**: for review and endorsement

Joerg Engelbergs and Olga Kholmanskikh presented the frequently asked questions document. CAT comments are awaited by 11 October 2023.
7.2.2. Update on the interphase with the Medical Device Regulation (MDR)

CAT: Ilona Reischl
Scope: Oral update
Action: for information
The CAT Chair provided an overview of all interphases between medicinal products and medical devices and the different groups in the member states, European Commission and EMA that are involved.

7.2.3. EPAR development

Scope: Information in the EPAR in case of withdrawal of the marketing authorisation before opinion
Action: for information
EMA explained the content of the EPAR in case the marketing authorisation application (MAA) is withdrawn before opinion. The withdrawal EPAR will be based on the latest adopted assessment report.

7.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

No items

7.4. Cooperation with the EU regulatory network

7.4.1. Support to member states for the assessment of ATMP Marketing Authorisation Applications

CAT: Ilona Reischl
Scope: Update following the teleconference regarding the general discussion on needs of member states for the assessment of ATMP marketing authorisation applications (MAAs)
Action: for information
The report of the ad-hoc teleconference held on 19 September 2023 was presented.

7.5. Cooperation with international regulators

7.5.1. ATMP cluster teleconference with US-FDA, Health Canada and PMDA (Japan)

CAT: Ilona Reischl
Scope: Update of the teleconference that took place on 28.09.2023
Action: for information
CAT Secretariat provided a short feedback from the discussions in the September ATMP cluster teleconference.

### 7.5.2. International Pharmaceutical Regulatory Programme (IPRP) Gene and Cell therapy working group

CAT: Pille Säälik

Scope: Update of the teleconference that took place on 28.09.2023

**Action:** for information

Pille Säälik provided a short feedback from the discussions in the recent IPRP Gene and cell therapy working group.

### 7.6. CAT work plan

#### 7.6.1. CAT work plan for 2024

CAT: Ilona Reischl

Scope: Brainstorming session on work plan topics for 2024

**Action:** for discussion

CAT held a first detailed discussion on the topics and activities that will be included in the CAT work plan for 2024.

#### 7.6.2. Guideline on quality, non-clinical and clinical requirement for investigational ATMPs in clinical trials

CAT: Ilona Reischl

Scope: Feedback from the drafting group discussion on the introduction, scope and general comments made by the stakeholders

**Action:** for discussion

During the drafting group, the CAT participants discussed the comments made on the following parts of the guideline: executive summary, introduction and scope. In addition, the general comments were discussed. Amendments to the guideline text were made.

### 7.7. Planning and reporting

No items

### 7.8. Others

#### 7.8.1. Training of CAT members and assessors

CAT: Marcos Timon
Committee for Advanced Therapies (CAT)
EMA/CAT/456007/2023

Scope: Training on Guideline on quality, non-clinical and clinical aspects of medicinal products containing genetically modified cells

Action: for information

The training by Marcos Timon on the Guideline on quality, non-clinical and clinical aspects of medicinal products containing genetically modified cells was attended by CAT members and colleagues in the national competent authorities (NCAs) dealing with ATMP assessment.

7.8.2. FDA Draft Guidance on Manufacturing Changes and Comparability for Human Cellular and Gene Therapy Products

CAT: Ilona Reischl

Scope: Draft guidance

Action: for information

The information was noted.


8. Any other business

Date of next CAT meeting:

30-31 October 2023

9. List of participants

Including any restrictions with respect to involvement of members / alternates / experts following evaluation of declared interests for the 04-06 October 2023 meeting.

<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
<th>Member State or affiliation</th>
<th>Outcome restriction following evaluation of e-DoI</th>
<th>Topics on agenda for which restrictions apply</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ilona Reischl</td>
<td>Chair</td>
<td>Austria</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Silke Dorner</td>
<td>Member</td>
<td>Austria</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Corina Spreitzer</td>
<td>Alternate</td>
<td>Austria</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Claire Beuneu</td>
<td>Member</td>
<td>Belgium</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Olga Kholmanskikh</td>
<td>Alternate</td>
<td>Belgium</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Rozalina Kulaksazova</td>
<td>Member</td>
<td>Bulgaria</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Role</td>
<td>State or affiliation</td>
<td>Outcome restriction following evaluation of e-DoI</td>
<td>Topics on agenda for which restrictions apply</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>-------------------------------</td>
<td>----------------------</td>
<td>-------------------------------------------------------------------------------------------------------------------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>Azra Selimovic</td>
<td>Member</td>
<td>Croatia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Petra Sokol</td>
<td>Alternate</td>
<td>Croatia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Isavella Kyriakidou</td>
<td>Alternate</td>
<td>Cyprus</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Petr Soukup</td>
<td>Member</td>
<td>Czechia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Ebru Karakoc Madsen</td>
<td>Member</td>
<td>Denmark</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Bibi Fatima Syed Shah</td>
<td>Alternate</td>
<td>Denmark</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Toivo Maimets</td>
<td>Member</td>
<td>Estonia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Pille Saalik</td>
<td>Alternate</td>
<td>Estonia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Heli Suila</td>
<td>Member</td>
<td>Finland</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Jean-Michel Race</td>
<td>Alternate</td>
<td>France</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Egbert Flory</td>
<td>Alternate (to CHMP representative)</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Maria Gazouli</td>
<td>Member</td>
<td>Greece</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Angeliki Rompoti</td>
<td>Alternate</td>
<td>Greece</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Balázs Sarkadi</td>
<td>Alternate</td>
<td>Hungary</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Maura O’Donovan</td>
<td>Member</td>
<td>Ireland</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Niamh Curran</td>
<td>Alternate</td>
<td>Ireland</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Concetta Quintarelli</td>
<td>Member</td>
<td>Italy</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Barbara Bonamassa</td>
<td>Alternate</td>
<td>Italy</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Una Riekstina</td>
<td>Member</td>
<td>Latvia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Raimondas Benetis</td>
<td>Alternate (to CHMP representative)</td>
<td>Lithuania</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Johannes Hendrikus Ovelgonne</td>
<td>Member</td>
<td>Netherlands</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Rune Kjeken</td>
<td>Member</td>
<td>Norway</td>
<td>Cannot act as rapporteur, other</td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Role</td>
<td>Member State or affiliation</td>
<td>Outcome restriction following evaluation of e-DoI</td>
<td>Topics on agenda for which restrictions apply</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>------------------------------------</td>
<td>----------------------------</td>
<td>-----------------------------------------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------</td>
</tr>
<tr>
<td>Dariusz Sladowski</td>
<td>Member</td>
<td>Poland</td>
<td>leadin/co-ordinating role or peer reviewer for</td>
<td></td>
</tr>
<tr>
<td>Maria Isabel Borba Vieira</td>
<td>Alternate (to CHMP representative)</td>
<td>Portugal</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Silviu Istrate</td>
<td>Member</td>
<td>Romania</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Margareta Fogelová</td>
<td>Alternate</td>
<td>Slovakia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Suzana Vidić</td>
<td>Alternate</td>
<td>Slovenia</td>
<td>No participation in final deliberations and voting on:</td>
<td>2.13.3 Kyrmiah ANX/009.6</td>
</tr>
<tr>
<td>Marcos Timón</td>
<td>Alternate (to CHMP representative)</td>
<td>Spain</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Maria Luttgen</td>
<td>Member</td>
<td>Sweden</td>
<td>Cannot act as rapporteur, other leading/co-ordinating role or peer reviewer for:</td>
<td></td>
</tr>
<tr>
<td>Charlotte Anderberg</td>
<td>Alternate</td>
<td>Sweden</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Kerstin Sollerbrant Melefors</td>
<td>Member</td>
<td>Patients' Representative</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Kieran Breen</td>
<td>Member (Vice-Chair)</td>
<td>Patients' Representative</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Federica Chiara</td>
<td>Alternate</td>
<td>Patients' Representative</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Catherine Milne</td>
<td>Observer/Alternate</td>
<td>EDQM</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Torbjorn Callreus</td>
<td>Expert</td>
<td>Malta</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Joerg Engelbergs</td>
<td>Expert</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Sandrine Tinton</td>
<td>Expert</td>
<td>Belgium</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Evelyne Pirotte</td>
<td>Expert</td>
<td>Belgium</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Xavier Pepermans</td>
<td>Expert</td>
<td>Belgium</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Frederic Klein</td>
<td>Expert</td>
<td>Belgium</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Role</td>
<td>Member State or affiliation</td>
<td>Outcome restriction following evaluation of e-DoI</td>
<td>Topics on agenda for which restrictions apply</td>
</tr>
<tr>
<td>--------------------</td>
<td>---------</td>
<td>----------------------------</td>
<td>--------------------------------------------------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>Ingrid Bourges</td>
<td>Expert</td>
<td>Belgium</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Joelle Warlin</td>
<td>Expert</td>
<td>Belgium</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Kimberly Vanthuyne</td>
<td>Expert</td>
<td>Belgium</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Anne Rousseau</td>
<td>Expert</td>
<td>Belgium</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Emilie Perez</td>
<td>Expert</td>
<td>Belgium</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Filip Van Nuffel</td>
<td>Expert</td>
<td>Belgium</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Mirna Golemović</td>
<td>Expert</td>
<td>Croatia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Nives Bebek Bestvina</td>
<td>Expert</td>
<td>Croatia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Dijana Derganc</td>
<td>Expert</td>
<td>Croatia</td>
<td>No interests declared</td>
<td></td>
</tr>
</tbody>
</table>

A representative from the European Commission attended the meeting

Meeting run with support from relevant EMA staff
10. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

For a list of acronyms and abbreviations, see:
List of abbreviations used in EMA human medicines scientific committees and CMDh documents, and in relation to EMA’s regulatory activities

Evaluation of ATMPs (section 2)

This section lists applications for marketing authorisations of new Advanced Therapy Medicinal Products (ATMPs) that are to be discussed by the Committee. It also lists Post-authorisation activities (section 2.11-2.13) and any ATMP related inspection requests (section 2.14).

New applications (sections 2.1. to 2.9.)

Section 2.1 is for ATMPs nearing the end of the evaluation and for which the CAT is expected to adopt a draft opinion at this meeting on whether marketing authorisation should be granted. Once adopted, the CAT opinion is transmitted to the CHMP for final adoption. The CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU. More information on the evaluation of ATMPs can be found here.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:

The assessment of an application for a new medicine takes up to 210 ‘active’ days. This active evaluation time is interrupted by at least one ‘clock-stop’ during which time the applicant prepares the answers to questions from the CAT. The clock stop happens after day 120 and may also happen after day 180, when the CAT has adopted respectively a Day 120 list of questions (section 2.4) or a List of outstanding issues to be addressed by the company, which is listed in the agenda under sections 2.7 (Ongoing evaluation procedures (section 2.3). Section 2.6 also includes the CAT discussions at any other timepoint of the evaluation procedure of new applications.

Oral explanation (section 2.2.)

Prior to adoption of the CAT opinion, marketing authorisation applicants are normally invited to the CAT plenary meeting to address questions raised by the Committee.

Oral explanations normally relate to ongoing applications, but they can also relate to any other issue for which the CAT would like to discuss with company representatives in person.

New applications (section 2.7.)

In this section, information is included on upcoming marketing authorisation applications for ATMPs, as well as information on appointment of Rapporteurs for new ATMP applications.
Withdrawal of applications (section 2.8.)

This section includes information on marketing authorisation applications that are withdrawn by the applicant. Applicants may decide to withdraw applications at any stage during the assessment and a CAT opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 (section 2.9.)

This section lists applications for new marketing authorisation for ATMPs for which the applicant has requested a re-examination of the opinion previously issued by the CHMP. Similar to the initial evaluation of a marketing authorisation of an ATMP, CAT will adopt a draft re-examination opinion, which is transmitted to the CHMP for final adoption.

Companion diagnostics (section 2.10)

This section lists applications for initial and follow-on consultation of companion diagnostics.

Post-authorisation activities (section 2.11-2.13.)

Section 2.11 lists type II variations, including extension of indication applications and re-examination procedures for type II variations for which the applicant has requested re-examination of the opinion previously issued by the CHMP. Section 2.12 list extension application according to Annex I of Reg. 1234/2008 and section 2.13 includes all other post-authorisation activities concerning authorised ATMPs that are not covered elsewhere in the agenda such as post-authorisation measures, annual reassessments, 5-year renewals, supply shortages, quality defects. Issues that have been discussed at the previous meeting of the PRAC, the EMA’s committee responsible for evaluating and monitoring safety issues for medicines, will also be included here.

GMP and GCP Inspections Issues (section 2.14.)

This section lists inspections that are undertaken for ATMPs. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Certification of ATMPs (section 3)

This section includes the scientific evaluation by the CAT of quality and non-clinical data that small and medium-sized enterprises have generated at any stage of the ATMP development process. More information on the ATMP certification procedure can be found here.

Scientific Recommendation on Classification of ATMPs (Section 4)

This section includes the scientific recommendation by the CAT on whether medicines based on genes, cells or tissues meet the scientific criteria that define ATMPs. More information on the ATMP classification procedure, including the outcomes of finalised classifications, can be found here.

Scientific Advice (section 5)

This section includes all scientific advice given to companies during the development of an ATMP. Information related to the number of ATMP related scientific advices discussed by CAT can be found in the CAT Monthly reports. Further information on SAWP can be found here.

Pre-Authorisation (section 6)

Paediatric Investigation Plan (PIP)

This section includes the discussion of an ATMP before a formal application for marketing authorisation
is submitted. These cases refer for example to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation: in case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

CAT contributes to the evaluation of a Paediatric Investigation Plan (PIPs) for ATMPs by the Paediatric Committee. These PIPs are included in this section of the Agenda.

**ITF Briefing meeting in the field of ATMPs**

This section refers to briefing meetings of the Innovation Task Force and International co-operations activities of the CAT

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes of meetings with applicants developing ATMPs and of other ITF meetings of interest to the CAT are included in this section of the agenda. Further information on the ITF can be found [here](#).

**Priority Medicines (PRIME)**

This section includes the new requests for eligibility to PRIME for ATMPs under development, the discussions in CAT of these eligibility requests and the final recommendations for eligibility of ATMPs adopted by CHMP.

CAT will appoint one of its members as the CAT sponsor for each new ATMP eligibility request who will lead the CAT discussion based on the recommendation from the SAWP.

**Organisational, regulatory and methodological matters (section 7)**

This section includes topics related to regulatory and procedural guidance, CAT workplan, CAT meeting organisation (including CAT membership), planning and reporting, co-ordination with other committees, working parties and scientific advisory groups.

Furthermore, this section refers to the activities of the CAT drafting groups developing scientific guidelines for gene therapy medicinal products and for cell-based medicinal products, cooperation within the EU regulatory network and international regulators as well as direct interaction with interested parties. It also includes topics of scientific interest for the Committee that are not directly related to the work of the CAT drafting groups or CAT associated working parties.

**Any other business (section 8)**

This section is populated with miscellaneous topics not suitable under the previous headings.

More detailed information on the above terms can be found on the EMA website: [www.ema.europa.eu/](http://www.ema.europa.eu/)